



ELSEVIER

Contents lists available at ScienceDirect

Psychiatry Research

journal homepage: www.elsevier.com/locate/psychres

Short communication

Schizophrenia in high risk opioid users: A short communication on an autopsy study

Alan Watkins^a, Ann John^a, Ceri Bradshaw^b, Jenna Jones^a, Matthew Jones^{a,*}^a Health Services Research Team, Level 2, ILS2, Swansea University School of Medicine, Swansea SA28PP, United Kingdom^b Swansea University College of Human and Healthcare Sciences, Swansea SA28PP, United Kingdom

ARTICLE INFO

Keywords:

Opioids
Schizophrenia
Overdose death

ABSTRACT

The prevalence of schizophrenia among high risk opioid users was investigated as part of a wider investigation into opioid-related deaths. We found that over 6% of our sample of 312 decedents of opioid overdose had received a schizophrenia related diagnosis over a 36 month period prior to their death. This represents a near 8× increase on previously estimated period prevalence of schizophrenia in the general population. Though not conclusive, our findings raise questions about the extent to which opioid drugs are used by people with schizophrenia, and about how to best address high risk opioid use in people with schizophrenia.

1. Introduction

The relationship between schizophrenia and the problematic use of psychotropic substances, including opioid addiction and dependence has been well documented (Batel, 2000). To investigate the period prevalence of schizophrenia amongst opioid users at high risk of overdose, we conducted an autopsy study using linked and anonymised routine data.

2. Methods

We identified decedents of opioid overdose who died in Wales, a country in the UK with a population of approximately 3 million, between 1/1/2012 and 31/12/2015 by searching Office for National Statistics (ONS) mortality records. ONS mortality data is coded using the tenth revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) medical coding system (World Health Organisation, 2018). We used codes diagnostic codes F11–F19 (mental and behavioural disorders due to psychoactive substance use), X40-69 (unintentional and intentional poisoning by and exposure to narcotics and psychodysleptics, X85 (assault by drugs, medicaments and biological substances) and Y10-19 (poisoning by and exposure to narcotics and psychodysleptics) and object codes T40.0-T40.4 to identify opioid overdose deaths.

ONS mortality records were linked with NHS Wales Informatics Service (NWIS) hospital and General Practice (GP) datasets. The matching algorithm used to link data brought in to the databank was

devised at NWIS, and applies deterministic and probabilistic routines in a logical sequence. This approach to linkage of routine NWIS data in the Secure Anonymised Information Linkage (SAIL) databank allows for consistently accurate matching, demonstrating high specificity (> 99%) and sensitivity (> 95%) (Lyons et al., 2009).

Demographic, identifiable data were then separated from clinical data and records were each assigned a unique and encrypted Anonymised Linkage Field (ALF) number. Non-identifiable demographic data were then recombined with clinical data by ALF number; meaningless outside of the gateway allowing for privacy protection. Once the linked data were anonymised, they were analysed in the SAIL gateway (Jones et al., 2014; Lyons et al., 2009).

We searched for schizophrenia related codes in GP and hospital records of decedents of opioid overdose within our sample dataset. We used a coding framework previously applied by John and colleagues (John et al., 2018). Hospital data were coded using the ICD-10 system (diagnostic codes F20-F29), whilst the Read Clinical Terms Version 2 (CTV2) coding framework (NHS Digital, 2018) is used to record GP episodes including events related to patient care, as well as administrative tasks, in Welsh NHS primary care services. We limited our search to capture data related to diagnostic codes which were attached to decedent's hospital and GP records during a period of 36 months prior to death. To help contextualise our findings, we also searched for diagnoses of depressive disorders using a coding framework devised by John and colleagues (John et al., 2016). We chose a 36 month observation period prior to overdose death as during this time decedents could be considered as being at high risk of opioid overdose.

* Corresponding author.

E-mail address: m.b.jones@swansea.ac.uk (M. Jones).<https://doi.org/10.1016/j.psychres.2019.04.026>

Received 26 February 2019; Received in revised form 25 April 2019; Accepted 25 April 2019

Available online 26 April 2019

0165-1781/ © 2019 Elsevier B.V. All rights reserved.




Fig. 1. Deaths per year.

3. Results

We found that a limited library of diagnostic codes related to schizophrenia had been attached to decedent's hospital and GP records in the 3 years prior to death. A total of seven ICD-10 'F' codes describing schizophrenia, schizotypal and delusional disorders were found, and six Read CTV2 codes describing schizophrenia and schizophrenia spectrum disorder related diagnoses, including schizoaffective disorder; paranoid psychosis; and delusional disorder.

We found that one or more of the schizophrenia related ICD-10 and/or Read CTV2 diagnostic codes had been attached to the hospital and/or GP records of 19 distinct decedents representing over 6% of our sample of decedents ($n = 312$) in the 36 months prior to death. Stratified by year, we found that deaths increased over the course of the observation period (Fig. 1). The decedents did not differ significantly from the wider sample in terms of gender ratio (73.68% male vs. 73.08% in the wider sample) and mean age at death (39.94 [13.59] vs. 40.72 [11.92]).

Most decedents had received a primary diagnosis at hospital admission or had both GP and hospital contact ($n = 8$, 5.12%), whilst a minority were recorded as having GP contact only ($n = 3$, 0.96%). These results are summarised in Table 1.

Over the 36 months, 73.68% of the decedents who received a schizophrenia related diagnosis were diagnosed as having schizophrenia, paranoid or unspecified ($n = 14$). Half ($n = 7$) of these overlapped with the next largest group, those who received a diagnosis of schizotypal disorder 57.89% ($n = 11$). The remaining diagnosis received were 15.79% ($n = 3$) schizoaffective disorder; 15.79% ($n = 3$) unspecified paranoid state; 10.53% ($n = 2$) unspecified psychotic disorder; and 5.26% ($n = 1$) folie à deux.

In terms of intent, we found that 89.47% ($n = 17$) of decedents were found to have died of accidental overdose, whilst the remaining deaths ($n = 2$, 10.53%) were of undetermined intent.

Table 1
GP and Hospital data.

GP and hospital record codes	$n = 312$ n	%
GP Episode only	3	0.96
Hospital Admission only	8	2.56
Both GP and Hospital	8	2.56
Total	19	6.09

To help contextualise our findings, we searched for diagnoses of depressive disorder attached to GP and hospital records amongst our sample. We found that 8.97% ($n = 28$) of our sample received a diagnosis of depressive disorder in the 3 years prior to their death.

4. Discussion

In 2008 McGrath and colleagues (McGrath et al., 2008) carried out a comprehensive systematic review of observational studies of the epidemiology of schizophrenia. They identified 34 studies concerned with the period prevalence of schizophrenia in the general population. By abstracting data from these studies, the authors found an estimated mean annual period prevalence of schizophrenia in the general population of 5.7 per 1000 people. Compared to McGrath et al.'s findings, our data suggests that the prevalence of schizophrenia spectrum disorder in high risk opioid users might be over 8 times the prevalence in the general population. However, in utilising John et al.'s coding framework, we included cases of schizotypal disorder, schizoaffective disorder and unspecified paranoid and psychotic states. As such it could be argued that we are not making a direct comparison with schizophrenia as defined in McGrath et al.'s study.

We found significant overlap between those who received a diagnosis of schizophrenia and those who received a diagnosis of schizotypal disorder. These data support the findings of Hjorthøj et al. (2018), who found evidence for an association with opioid drug use and conversion of schizotypal disorder to schizophrenia.

The prevalence of depression amongst the total sample did not differ significantly from the European average prevalence of depressive disorder as estimated by the authors of the ODIN study who found an average overall prevalence of 8.56% (Ayuso-Mateos et al., 2001).

Although these data are inconclusive, they do raise questions related to high risk opioid use and schizophrenia. As most deaths were found to be accidental, the first is to what extent do people with schizophrenia spectrum disorders self-medicate with opioid drugs and place themselves at risk of overdose. There are certainly qualitative data to support the notion that illicit drugs including heroin are used by people with schizophrenia to self-medicate (Asher and Gask, 2010). Our data contradicts some (of the relatively scarce) quantitative data in this area suggesting that high-risk opioid use is either not associated, or is negatively associated with psychotic illness (Farrell et al., 2002; Sørensen et al., 2005). Another is whether enough being done to address high risk opioid use in patients with schizophrenia. Certainly, the deleterious effect of comorbid substance misuse disorder on health outcomes related to schizophrenia have been recognised for some time (Winklbaur et al., 2006), and yet specialist treatment pathways for opioid misuse in schizophrenic patients appear to have received little research attention or investment. Our sample included only high-risk opioid users who unfortunately died due to overdose, and so it is likely that high risk opioid use in this group, who are already known to suffer high levels of premature death, is more common than our sample suggests.

The authors welcome further research to address these questions and further investigate the relationship between schizophrenia and high-risk opioid use.

Acknowledgments

This study was supported by the Wales Centre for Primary and Emergency Care Research (PRIME). Data scoping, capture, linkage and anonymisation were carried out by SAIL.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.psychres.2019.04.026.

References

- Asher, C.J., Gask, L., 2010. Reasons for illicit drug use in people with schizophrenia: qualitative study. *BMC Psychiatry* 10, 94. <https://doi.org/10.1186/1471-244X-10-94>.
- Ayuso-Mateos, J.L., Vázquez-Barquero, J.L., Dowrick, C., Lehtinen, V., Dalgard, O.S., Casey, P., Wilkinson, C., Lasa, L., Page, H., Dunn, G., Wilkinson, G., Ballesteros, J., Birkbeck, G., Børve, T., Costello, M., Cuijpers, P., Davies, I., Diez-Manrique, J.F., Fenlon, N., Finne, M., Ford, F., Gaité, L., Gomez del Barrio, A., Hayes, C., Herrán, A., Horgan, A., Koffert, T., Jones, N., Lehtilä, M., McDonough, C., Michalak, E., Murphy, C., Nevra, A., Nummelin, T., Sohlman, B., 2001. Depressive disorders in Europe: prevalence figures from the ODIN study. *Br. J. Psychiatry* 179, 308–316. <https://doi.org/10.1192/bjp.179.4.308>.
- Batel, P., 2000. Addiction and schizophrenia. *Eur. Psychiatry* 15, 115–122. [https://doi.org/10.1016/S0924-9338\(00\)00203-0](https://doi.org/10.1016/S0924-9338(00)00203-0).
- Farrell, M., Boys, A., Bebbington, P., Brugha, T., Coid, J., Jenkins, R., Lewis, G., Meltzer, H., Marsden, J., Singleton, N., Taylor, C., 2002. Psychosis and drug dependence: results from a national survey of prisoners. *Br. J. Psychiatry* 181, 393–398. <https://doi.org/10.1192/bjp.181.5.393>.
- Hjorthøj, C., Albert, N., Nordentoft, M., 2018. Association of substance use disorders with conversion from schizotypal disorder to schizophrenia. *JAMA Psychiatry* 75, 733–739. <https://doi.org/10.1001/jamapsychiatry.2018.0568>.
- John, A., McGregor, J., Fone, D., Dunstan, F., Cornish, R., Lyons, R.A., Lloyd, K.R., 2016. Case-finding for common mental disorders of anxiety and depression in primary care: an external validation of routinely collected data. *BMC Med. Inform. Decis. Mak.* 16, 35. <https://doi.org/10.1186/s12911-016-0274-7>.
- John, A., McGregor, J., Jones, I., Lee, S.C., Walters, J.T.R., Owen, M.J., O'Donovan, M., DelPozo-Banos, M., Berridge, D., Lloyd, K., 2018. Premature mortality among people with severe mental illness — new evidence from linked primary care data. *Schizophr. Res.* 199, 154–162. <https://doi.org/10.1016/j.schres.2018.04.009>.
- Jones, K.H., Ford, D.V., Jones, C., Dsilva, R., Thompson, S., Brooks, C.J., Heaven, M.L., Thayer, D.S., McNeerney, C.L., Lyons, R.A., 2014. A case study of the secure anonymous information linkage (SAIL) gateway: a privacy-protecting remote access system for health-related research and evaluation. *J. Biomed. Inform.* 50, 196–204. <https://doi.org/10.1016/j.jbi.2014.01.003>.
- Lyons, R.A., Jones, K.H., John, G., Brooks, C.J., Verplancke, J.P., Ford, D.V., Brown, G., Leake, K., 2009. The SAIL databank: linking multiple health and social care datasets. *BMC Med. Inform. Decis. Mak.* 9, 3. <https://doi.org/10.1186/1472-6947-9-3>.
- McGrath, J., Saha, S., Chant, D., Welham, J., 2008. Schizophrenia: a concise overview of incidence, prevalence, and mortality. *Epidemiol. Rev.* 30, 67–76. <https://doi.org/10.1093/epirev/mxn001>.
- NHS Digital, 2018. Read Codes - NHS Digital. URL <https://digital.nhs.uk/services/terminology-and-classifications/read-codes> (Accessed 04 April 2019).
- Sørensen, H.J., Jepsen, P.W., Haastrup, S., Juel, K., 2005. Drug-use pattern, comorbid psychosis and mortality in people with a history of opioid addiction. *Acta Psychiatr. Scand.* 111, 244–249. <https://doi.org/10.1111/j.1600-0447.2004.00445.x>.
- World Health Organisation, 2018. ICD-10 online versions. URL <https://www.who.int/classifications/icd/icdonlineversions/en/> (Accessed 04 April 2019).
- Winklbaur, B., Ebner, N., Sachs, G., Thau, K., Fischer, G., 2006. Substance abuse in patients with schizophrenia. *Dialogues Clin. Neurosci.* 8, 37–43.